

## Concordance Table for ANZFFR Data Dictionary Patient Level Audit

Date introduced to Registry	DD Variable	Change Description	Old Coding Frame	New Coding Frame	Changes on Documents
July 2022	2.02, 2.03, 2.04 Primary, Second and Third Index Fracture sites	Upper humerus changed to Proximal humerus in all three DD items			Patient Level Audit form Data dictionary Registry Current forms March 2022-June 2023
July 2022	2.05 Not Appropriate for Further Assessment	To remove the double negative aspect, the title is changed to Appropriate for Further Assessment and the answers remain the same as Yes and No. This is simpler and clearer.			Patient Level Audit form Data dictionary Registry Current forms March 2022-June 2023
July 2022	6.02 Reason Treatment not Recommended	Very occasionally a person will not require treatment because all assessments indicate that treatment is not required. Additional option is added:  "All assessments indicate treatment not required at present".			Patient Level Audit form Data dictionary Registry Current forms March 2022-June 2023



		Additional option added related to bisphosphonates and dental problems.  "History of Osteonecrosis of the Jaw or significant active dental issue or planned dental treatment"			
July 2023	7.03 16-Week Residence	To enable interoperability the coding frame needs to match 7.04 Place of residence at 120-day follow- up from ANZHFR	<ol> <li>Private residence (including unit in retirement village)</li> <li>Residential aged care facility</li> <li>Other</li> <li>Not known</li> </ol>	1 Private residence (including unit in retirement village) 2 Residential aged care facility 3 Rehabilitation unit public 4 Rehabilitation unit private 5 Other hospital / ward / specialty 6 Deceased 7 Short term care in residential care facility (New Zealand only) 97 Other 99 Not known	Patient Audit Form Data Dictionary Registry from 1st July 2023
July 2023	7.04 16 Week Mobility	To enable interoperability the coding frame needs to match 7.06 Post-admission walking ability at 120-day follow-up from ANZHFR	1.Usually walks without walking aids 2.Usually walks with either a stick or crutch 3.Usually walks with two aids or frame (with or without assistance of a person)	<ul><li>1 Usually walks without walking aids.</li><li>2 Usually walks with either a stick or crutch.</li><li>3 Usually walks with two aids or frame.</li></ul>	Patient Audit Form Data Dictionary Registry from 1 <sup>st</sup> July 2023



			4.Usually uses a wheelchair / bed bound 9.Not known	4 Usually uses a wheelchair / bed bound. 8 Not relevant 9 Not known.	
July 2023	1.06 Sex of patient	To match ANZHFR for interoperability	1 Male 2 Female 3 Other	1 Male 2 Female 3 Intersex or indeterminate 4 Not stated / inadequately described	Patient Audit Form Data Dictionary Registry from 1 <sup>st</sup> July 2023
July 2023	1.13 Age Derived	To allow calculation of age based on date of birth	New data variable	3 digits for age of person	Data dictionary Registry from 1 <sup>st</sup> July 2023
July 2023	2.05 Appropriate for further assessment	The wording was still confusing in the definition. This is now set so that an answer of YES means continue and an answer of NO ends the data collection for this patient after answering 2.06.	Has a clinical decision has been made that the clinical context of this patient means that any treatment for falls, or fracture prevention is not appropriate	Has a clinical decision been made that the clinical context of this patient means that any treatment for falls, or fracture prevention IS appropriate?	Data dictionary from 1 <sup>st</sup> July 2023
July 2023	2.06 Reason not appropriate for further assessment	Feedback from users requested an option for people not resident in Australia or New Zealand. There was also a request to remove the word dialysis and to remove the "no obvious reason" item.	1.Deceased 2.Terminal illness / palliative care 3.Frailty, life expectancy of less than a year 4 End stage renal failure – dialysis 5.Advanced malignancy # not due to metastasis.	1. Deceased 2.Terminal illness / palliative care 3. Frailty, life expectancy of less than a year 4. End stage renal failure	Patient Audit Form Data Dictionary Registry from 1 <sup>st</sup> July 2023



					AND FR AGIL
			6. No obvious reason 7. Other	<ul><li>5. Advanced malignancy # not due to metastasis.</li><li>6. Usual residence not in New Zealand or Australia</li><li>7. Other</li></ul>	
July 2023	2.07 Date Not Appropriate for Further Assessment	New variable to document if decision is made within the 12 weeks required for Clinical Standards for FLS in NZ		DD/MM/YY	Patient Audit Form Data Dictionary Registry from 1 <sup>st</sup> July 2023
July 2023	3.09 Current Osteoporosis specific treatment	In the comments section the definitions for each medication required clarification – in most cases this was a change from "prescribed" to "administered".  In Australia information will be only from patient interview. In NZ information is from a combination of patient interview and electronic linkage	A patient is to be considered as 'on/taking' osteoporosis specific treatment if:  • For oral bisphosphonates, prescribed in the last 4 weeks.  • For Zoledronate, prescribed in the last 24 months.  • For Denosumab, prescribed the last 6 months.  • For Teriparatide, prescribed in the last 7 days.  • For Romosozumab, prescribed in the last month.  These medications may be prescribed with or	A patient is to be considered as 'on/taking' osteoporosis specific treatment if:  • For oral bisphosphonates, prescribed in the last 12 weeks.  • For Zoledronate, administered in the last 24 months.  • For Denosumab, administered the last 6 months.  • For Teriparatide, administered in the last 7 days.  • For Romosozumab, administered in the last month.	Data dictionary from 1 <sup>st</sup> July 2023



	without calcium and / or vitamin D. If unsure as to the type of Hormone replacement therapy (HRT) please select Systemic Oestrogen & Progesterone.	These medications may be prescribed with or without calcium and / or vitamin D. If unsure as to the type of Hormone replacement therapy (HRT) please select Systemic Oestrogen & Progesterone.
--	--	--



July 2023	3.11 Thoraco-Lumbar spine imaging	Changes are made to improve clarity by adding an option that there was no imaging performed – so that this could be removed from the comments section. In the comments section lateral chest x-ray has been included as an option.	1. Fracture identified 2. No fracture identified 3. No images available 9. Not known  Comments The imaging may be in the form of a thoraco-lumbar spine x-ray, bone scan, CT scan, MRI or vertebral fracture assessment using a DXA scan. Answer "No fracture identified" if (a) imaging has been done and there were no vertebral fractures identified. OR (b) there has not been any imaging of the thoraco-lumbar	1. Fracture identified 2. No fracture identified 3. No imaging of thoraco-lumbar spine performed or report not available 9. Not known  Comments The imaging may be in the form of a thoraco- lumbar spine x-ray, lateral chest x-ray, bone scan, CT scan, MRI or vertebral fracture assessment using a DXA scan. Answer "No fracture identified" if imaging	Patient Audit Form Data Dictionary Registry from 1st July 2023
			spine.	has been done and there were no vertebral fractures identified	
July 2023	4.09 Information about Nymbl Provided	New variable to document whether information about the Nymbl smart phone application was provided to the patient.		1. Yes. 2. No.	Patient Audit Form Data Dictionary Registry from 1st July 2023
July 2023	5.01 DXA ordered or not	Option 3 needed clarifying  Further to option 3 if a DXA was not being ordered, and	<ol> <li>Ordered</li> <li>Declined</li> <li>Done in last 24 months and not being repeated</li> </ol>	<ol> <li>Ordered</li> <li>Declined</li> <li>Done in last 24 months and not being</li> </ol>	Patient Audit Form Data Dictionary Registry from 1 <sup>st</sup> July 2023
		one had been done in the last 24 months, feedback	<ul><li>4. Not appropriate</li><li>5. Not available</li></ul>	repeated at this time. 4. Not appropriate	





				10. Denosumab	
				11. Teriparatide	
				12. Testosterone	
				13. Systemic	
				Oestrogens	
				14. Systemic	
				Oestrogen &	
				Progesterone	
				15. Romosozumab	
				16. Raloxifene	
				99. Not known	
July 2023	6.02	A change in the order of the	1. Poor renal function	1. All assessments	Patient Audit Form
	Reason treatment	options was recommended.	2. Poor swallowing, severe	indicate treatment	Data Dictionary
	not recommended		GORD, Barrett's	not required at	Registry
		Typo in comments corrected	oesophagus, achalasia	present	from 1st July 2023
			3. Advanced frailty, life	2. Poor renal function	-
			expectancy of less than a	3. Poor swallowing,	
			year	severe GORD,	
			4. Long term	Barrett's	
			bisphosphonate	oesophagus,	
			treatment, so no further	achalasia	
			fracture risk benefit.	4. Advanced frailty, life	
			5. Treatment indicated, but	expectancy of less	
			no funded alternatives	than a year	
			available within Pharmac	5. Long term	
			(NZ) or PBS (Aust)	bisphosphonate	
			critéria	treatment, so no	
			6. Atypical femur fracture	further fracture risk	
			7. History of	benefit.	
			Osteonecrosis of the Jaw	6. Treatment indicated,	
			or significant active	but no funded	
			dental disease or	alternatives	
			planned dental treatment	available within	



			8. All assessments indicate treatment not required at present 9. No obvious reason  Note: long term bisphosphonate treatment means the patient has received many years of bisphosphonates (e.g., more than 5 years) and continuing bisphosphonate therapy will reduce fracture risk further.	Pharmac (NZ) or PBS (Aust) criteria 7. Atypical femur fracture 8. History of Osteonecrosis of the Jaw or significant active dental disease or planned dental treatment 9. No obvious reason	
				Note: long term bisphosphonate treatment means the patient has received many years of bisphosphonates (e.g., more than 5 years) and continuing bisphosphonate therapy will not reduce fracture risk further.	
July 2023	6.08 Standard Information Package Date	New variable to document whether information provided in time to meet Clinical Standards for FLS in NZ		DD/MM/YYYY  Code for not done 99/99/9999	Patient Audit Form Data Dictionary Registry from 1st July 2023



	T	T	T	Г. =	
July 2023	7.06	An option added to account	Recommended but	Recommended but	Patient Audit Form
	16-week	for a delay in completing the	declined	declined	Data Dictionary
	medication	Bone Health assessment.	Awaiting specialist	2. Awaiting specialist	Registry
			opinion	opinion	from 1 <sup>st</sup> July 2023
		The definition is added to	3. Alendronate	3. Clinical assessment	
		the comments section.	4. Risedronate	not yet completed.	
			5. Zoledronate	4. Alendronate	
			6. Denosumab	5. Risedronate	
			7. Teriparatide	6. Zoledronate	
			8. Testosterone	7. Denosumab	
			9. Systemic Oestrogens	8. Teriparatide	
			10. Systemic Oestrogen &	9. Testosterone	
			Progesterone	10. Systemic	
			11. Romosozumab	Oestrogens	
			12. Raloxifene	11. Systemic	
			99. Not known	Oestrogen &	
				Progesterone	
				12. Romosozumab	
				13. Raloxifene	
				99. Not known	
				Answer 3., if the	
				treatment decision is	
				delayed due to	
				incomplete fracture	
				risk assessment, e.g.,	
				awaiting DXA result.	
July 2023	8.05	To align with the definitions	A patient is to be	A patient is to be	Data dictionary
July 2020	52-week	in 3.09, the definitions in the	considered as 'on/taking	considered as	from 1 <sup>st</sup> July 2023
	medication	Comments section have	bone protection	'on/taking bone	
	modiodion	been changed. These are	medication' if:	protection medication'	
		mostly changes of the word	For oral-osteoporosis	if:	
		prescribed to administered.	agents, patient prescribed	• For oral-osteoporosis	
		prescribed to administered.	in the last 12 weeks.	· ·	
			in the last 12 weeks.	agents, patient	



		In Australia information will be only from patient interview. In NZ information is from a combination of patient interview and electronic linkage	<ul> <li>For Zoledronate, prescribed in the last 24 months</li> <li>For Denosumab, prescribed the last 6 months.</li> <li>For Teriparatide, prescribed in the last 7 days.</li> <li>For Romosozumab, prescribed in the last month.</li> </ul>	prescribed in the last 12 weeks. • For Zoledronate, administered in the last 24 months • For Denosumab, administered in the last 6 months. • For Teriparatide, administered in the last 7 days. • For Romosozumab, administered in the last month.	
July 2023	8.05 52-week medication	To add the option of "never started taking osteoporosis specific medication"	<ol> <li>No longer taking osteoporosis specific treatment.</li> <li>Alendronate</li> <li>Risedronate</li> <li>Zoledronate</li> <li>Denosumab</li> <li>Teriparatide</li> <li>Testosterone</li> <li>Systemic         <ul> <li>Oestrogens</li> <li>Systemic Oestrogen</li> <li>Progesterone</li> </ul> </li> <li>Romosozumab</li> <li>Raloxifene</li> </ol>	<ul> <li>0. Never started taking osteoporosis specific medication</li> <li>1. No longer taking osteoporosis specific treatment.</li> <li>2. Alendronate</li> <li>3. Risedronate</li> <li>4. Zoledronate</li> <li>5. Denosumab</li> <li>6. Teriparatide</li> <li>7. Testosterone</li> <li>8. Systemic</li> <li>Oestrogens</li> <li>9. Systemic Oestrogen</li> <li>&amp; Progesterone</li> <li>10. Romosozumab</li> <li>11.Raloxifene</li> </ul>	Patient Audit Form Data Dictionary Registry from 1st July 2023



_	_				
July 2023	8.06 Reason for no medication at 52 weeks	The definition of this variable was clarified by changing wording	What was the reason of the patient not continuing bone protection medication at 52 week follow up?	What was the reason for the patient not taking recommended osteoporosis specific treatment at 52 week follow up?	Data dictionary from 1 <sup>st</sup> July 2023
July 2023	9.01 Date of death	Clarification of the coding frame to be DD/MM/YYYY	//	DD/MM/YYYY	Registry only from 1 <sup>st</sup> July 2023
July 2023	4.07 Strength and Balance Referrals	Changes are to the comments section only. These are to clarify and document processes.	The FLS should record " Referred to a community strength and balance programme" when: The FLS has the sole option of referring to a community programme (no in-home programme available) The FLS is required to refer to a community programme which itself assesses suitability for an in-home programme.	The FLS should record "Referred to a community strength and balance programme" when: The referrers have the sole option of referring to a community programme (no in-home programme available) The referrer is required to refer to a community programme which itself assesses suitability for an in- home programme.  For options 1, 2, 6, 7 and 9, no date is required for variable 4.08 Strength and Balance Referral Date.	Data dictionary from 1st July 2023
July 2023	4.08	Change only in comments section. Clarification about the date of a referral if the		If the patient has been an inpatient, this would be the discharge date.	Data dictionary from 1 <sup>st</sup> July 2023



	Strength and Balance Referral Date	patient has been an inpatient.			
Facility Level Audit					
December	3.02 FLS	This variable retired due to		Retired December	Removed from current
2022	Identification	the collection of the same		2022	Data Dictionary
	Methods	information in the patient			
		level audit variable			